Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Research and Innovation Action · Running

LIBRA Light Based Multisensing Device for Screening of Pathogens and Nutrients in Bioreactors

Coordinator
Ethnicon Metsovion Polytechnion, Greece
Runs
1 January 2023 to 30 June 2026
Status
Running
EU funding
€4.4m
Total cost
€4.4m
Partners
20 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101093150

What the project is doing

In the project's own words, from its summary on CORDIS.

The bioreactor industry is currently flourishing with a global market valued estimated at 2.3 B€ in 2020 and predicted to exceed 6.6 B€ euro by 2030, growing at a rate of 10.7% CAGR. Despite this impressive growth, there are challenges which can significantly impede the further advancement of bioreactors: Bioproducts can be sustainable and competitive only if reliable and contamination-free production is ensured. Currently, there is no catholic solution to this issue.

To this end, LIBRA project introduces a benchtop smart multi-sensing system for the in-line automatable screening of cultivation processes in bioreactors. The LIBRA sensing technology lies in the use of light based integrated on-chip, real time sensors. A novel integration procedure of the photonic platforms together with disposable microfluidic modules and biofunctionalization units will result in a modular system with interchangeable components enabling the screening of nutrients and pathogens in bioreactor samples, according to the end users need.

Furthermore, the LIBRA system will be able to be attached and integrated to various bioreactor systems regardless of their form factors, spanning from stirred tank bioreactors to single use bioreactors (SUB). To achieve this, LIBRA will rely on a highly multi-disciplinary consortium comprising expertise and specialization in several fields spanning photonics, surface functionalization, microfluidics, advanced packaging and assembly, artificial intelligence and bioreactor manufacturers.

The exploitable results of LIBRA are expected to disrupt the current PIC-based sensing landscape, as estimated by the two business cases stemming from the project: the market revenues one year after the end of this project are expected to be €7.8 million growing to almost €59 million in 2032, and plethora of new IP and new business opportunities for the partners involved in the joint venture of LIBRA.

Topics

Who is involved

OrganisationCityCountryRole
Ethnicon Metsovion PolytechnionAthinaGreeceCoordinator
Csem Centre Suisse D'electronique Et De Microtechnique SA - Recherche Et DeveloppementNeuchatelSwitzerlandAssociatedpartner
Aarhus UniversitetAarhus CDenmarkParticipant
Aarhus UniversitetshospitalAarhusDenmarkParticipant
Optagon Fotoniki Idiotiki Kefalaiouchiki EtairiaPallini, AthinaGreeceParticipant
Phosprint Anonymi EtaireiaAgia Paraskevi AthinaGreeceParticipant
Fibo Labs OyHelsinkiFinlandParticipant
EcovamedChavilleFranceParticipant
Consiglio Nazionale Delle RicercheRomaItalyParticipant
Demcon Bunova B.v.EnschedeNetherlandsThird party
Demcon Engineering BVEnschedeNetherlandsThird party
Demcon Focal BVEnschedeNetherlandsThird party
Demcon High-Tech Systems Enschede BVEnschedeNetherlandsThird party
Demcon Industrial Systems Groningen BVEnschedeNetherlandsThird party
Demcon Innovation & Technology B.v.EnschedeNetherlandsThird party
Demcon Life Sciences & Health Enschede BVEnschedeNetherlandsParticipant
Demcon Life Sciences & Healtheindhoven B.v.BestNetherlandsThird party
Demcon Life Sciences & Health Maastricht B.V.EnschedeNetherlandsThird party
Lionix International B.v.EnschedeNetherlandsParticipant
Scinus Cell Expansion Netherlands B.v.ZeistNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI